Arrêt de service programmé du vendredi 10 juin 16h jusqu’au lundi 13 juin 9h. Pour en savoir plus
Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors

Abstract : Metastatic pancreatic ductal adenocarcinomas (PDACs) are now more effectively controlled using chemotherapy combinations such as FOLFIRINOX and gemcitabine plus nab-paclitaxel (NabP) regimens with a subset of patients who achieve a sustained tumor stabilization or response. The next challenge is to design maintenance therapies that result in continued tumor control with minimal toxicity. Quality of life should always be a priority in these patients with prolonged survival. Gradually tapering off the intensity of chemotherapy by suppressing drug(s) in the combination is one option. Thus, maintenance with 5-fluorouracil or gemcitabine as single agents after FOLFIRINOX or gemcitabine-NabP induction, respectively, seems to be a promising approach to minimize neurotoxicity while maintaining efficacy. Another option is to introduce maintenance drug(s) with different anti-tumoral actions. The recent example of olaparib in patients with BRCA mutated PDAC provides a promising proof-of-concept of a switch maintenance strategy in this setting.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Véronique Bourgeais Connectez-vous pour contacter le contributeur
Soumis le : mardi 13 juillet 2021 - 16:24:45
Dernière modification le : samedi 21 mai 2022 - 03:40:42

Lien texte intégral



Pascal Hammel, Carole Vitellius, Émeric Boisteau, Mathilde Wisniewski, Elise Colle, et al.. Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. Therapeutic Advances in Medical Oncology, SAGE Journals, 2020, 12, pp.175883592093794. ⟨10.1177/1758835920937949⟩. ⟨hal-03285853⟩



Consultations de la notice